Login to Your Account

Radiation Candidate a Keeper

Maxygen Has Maxi-Cash After Astellas Buyout of Perseid

By Tom Wall

Friday, March 18, 2011
Maxygen, Inc.'s shares and bank balance both grew rapidly on news that Tokyo-based partner Astellas Pharma Inc. exercised its option to buy out Maxygen's 83.3 percent equity interest in the companies' joint venture, Perseid Therapeutics LLC, for $76 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription